Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest

Ovid Therapeutics Inc.

2023-Q3 EPS reported -$0.52 revenue$222,800,000

Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.
Cash and equivalents $87.1M as of Sep 30, 2023, excluding the $30M received in Oct.
Net loss $11.3M ($0.16 per share) vs $12.0M ($0.17) in Q3 2022.
Takeda anticipates regulatory filings for soticlestat in fiscal year 2024; two Phase 3 trials on track.
OV329 expanding to IV formulation; IND expected H2 2024. OV350 (KCC2) IND also expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ovid Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 3, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2023 Financial Results and Corporate Updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-036563

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.